FCGR3A-eiwit (C-His, mens)

FCGR3A

CD16, CD16-II, CD16A, FCG3, FcgammaRIIIa, FCGR3, FCGRIII, FcGRIIIA, FCR-10, FCRIII, FCRIIIA, IGFR3, IMD20

C-His

< 1.0 EU per μg of the protein as determined by the LAL method

≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC. ≥ 90 % as determined by SEC-MALS (Routinely tested) .

1. Loaded Recombinant Human CD16a / FCGR3A Protein (F176, His Tag) (Cat: 10389-H08H) on His1K Biosensor, can bind anti-VEGFA (Research grade Bevacizumab Biosimilar) with an affinity constant of 1.9 μM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested) . 2. anti-VEGFA (Research grade Bevacizumab Biosimilar) captured on ProA chip, can bind Recombinant Human CD16a / FCGR3A Protein (F176, His Tag) (Cat: 10389-H08H) with an affinity constant of 2.67 μM as determined in an SPR assay (Biacore T200) (Routinely tested) . 3. Recombinant Human CD16a / FCGR3A Protein (F176, His Tag) (Cat: 10389-H08H) captured on CM5 Chip via Anti-his antibody chip, can bind anti-CD20 (Research grade Rituximab Biosimilar) with an affinity constant of 0.499 μM as determined in an SPR assay (Biacore T200) (QC tested) .

Met1-Gln208

The secreted recombinant human CD16a consists of 203 amino acids and has a predicted molecular mass of 23.3 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of human CD16a is approximately 45.2 kDa due to glycosylation. The molecular weight of this protein is around 36-48 kDa verified by SEC-MALS (Routinely tested) .

Human